193 related articles for article (PubMed ID: 36603729)
1. Enhanced glypican-3-targeted identification of hepatocellular carcinoma with liver fibrosis by pre-degrading excess fibrotic collagen.
Zhuo J; Wang Y; Hui H; Li C; Yang J; Zhang P; Fang C; Tian J
Acta Biomater; 2023 Mar; 158():435-448. PubMed ID: 36603729
[TBL] [Abstract][Full Text] [Related]
2. Development and
Ma XH; Wang S; Liu SY; Chen K; Wu ZY; Li DF; Mi YT; Hu LB; Chen ZW; Zhao XM
World J Gastroenterol; 2019 Jun; 25(24):3030-3043. PubMed ID: 31293339
[TBL] [Abstract][Full Text] [Related]
3. Collagenase Type I and Probucol-Loaded Nanoparticles Penetrate the Extracellular Matrix to Target Hepatic Stellate Cells for Hepatic Fibrosis Therapy.
Wang X; Zhang W; Zeng S; Wang L; Wang B
Acta Biomater; 2024 Feb; 175():262-278. PubMed ID: 38141933
[TBL] [Abstract][Full Text] [Related]
4. Detection of hepatocellular carcinoma in transgenic mice by Gd-DTPA- and rhodamine 123-conjugated human serum albumin nanoparticles in T1 magnetic resonance imaging.
Watcharin W; Schmithals C; Pleli T; Köberle V; Korkusuz H; Hübner F; Waidmann O; Zeuzem S; Korf HW; Terfort A; Gelperina S; Vogl TJ; Kreuter J; Piiper A
J Control Release; 2015 Feb; 199():63-71. PubMed ID: 25499552
[TBL] [Abstract][Full Text] [Related]
5. Glypican-3-targeted 89Zr PET imaging of hepatocellular carcinoma.
Sham JG; Kievit FM; Grierson JR; Miyaoka RS; Yeh MM; Zhang M; Yeung RS; Minoshima S; Park JO
J Nucl Med; 2014 May; 55(5):799-804. PubMed ID: 24627434
[TBL] [Abstract][Full Text] [Related]
6. Enhanced TfR1 Recognition of Myocardial Injury after Acute Myocardial Infarction with Cardiac Fibrosis via Pre-Degrading Excess Fibrotic Collagen.
Yang W; Wang Y; Li H; Liao F; Peng Y; Lu A; Tan L; Qu H; Long L; Fu C
Biology (Basel); 2024 Mar; 13(4):. PubMed ID: 38666825
[TBL] [Abstract][Full Text] [Related]
7. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions.
Wang HL; Anatelli F; Zhai QJ; Adley B; Chuang ST; Yang XJ
Arch Pathol Lab Med; 2008 Nov; 132(11):1723-8. PubMed ID: 18976006
[TBL] [Abstract][Full Text] [Related]
8. GPC3-targeted immunoPET imaging of hepatocellular carcinomas.
An S; Zhang D; Zhang Y; Wang C; Shi L; Wei W; Huang G; Liu J
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2682-2692. PubMed ID: 35147737
[TBL] [Abstract][Full Text] [Related]
9. Targeted-detection and sequential-treatment of small hepatocellular carcinoma in the complex liver environment by GPC-3-targeted nanoparticles.
Deng H; Shang W; Wang K; Guo K; Liu Y; Tian J; Fang C
J Nanobiotechnology; 2022 Mar; 20(1):156. PubMed ID: 35331259
[TBL] [Abstract][Full Text] [Related]
10. Additional value of SPIO-enhanced MR imaging for the noninvasive imaging diagnosis of hepatocellular carcinoma in cirrhotic liver.
Yoo HJ; Lee JM; Lee JY; Kim SH; Kim SJ; Han JK; Choi BI
Invest Radiol; 2009 Dec; 44(12):800-7. PubMed ID: 19838119
[TBL] [Abstract][Full Text] [Related]
11. Imaging the expression of glypican-3 in hepatocellular carcinoma by PET.
Wang Z; Han YJ; Huang S; Wang M; Zhou WL; Li HS; Wang QS; Wu HB
Amino Acids; 2018 Feb; 50(2):309-320. PubMed ID: 29204748
[TBL] [Abstract][Full Text] [Related]
12. Radiofluorinated GPC3-Binding Peptides for PET Imaging of Hepatocellular Carcinoma.
Li Y; Zhang J; Gu J; Hu K; Huang S; Conti PS; Wu H; Chen K
Mol Imaging Biol; 2020 Feb; 22(1):134-143. PubMed ID: 31044341
[TBL] [Abstract][Full Text] [Related]
13. Significance of Glypican-3 in Early Detection of Hepatocellular Carcinoma in Cirrhotic Patients.
Tahon AM; El-Ghanam MZ; Zaky S; Emran TM; Bersy AM; El-Raey F; A Z E; El Kharsawy AM; Johar D
J Gastrointest Cancer; 2019 Sep; 50(3):434-441. PubMed ID: 29623600
[TBL] [Abstract][Full Text] [Related]
14. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules.
Libbrecht L; Severi T; Cassiman D; Vander Borght S; Pirenne J; Nevens F; Verslype C; van Pelt J; Roskams T
Am J Surg Pathol; 2006 Nov; 30(11):1405-11. PubMed ID: 17063081
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma.
Liu H; Li P; Zhai Y; Qu CF; Zhang LJ; Tan YF; Li N; Ding HG
World J Gastroenterol; 2010 Sep; 16(35):4410-5. PubMed ID: 20845507
[TBL] [Abstract][Full Text] [Related]
16. Radiomics machine-learning signature for diagnosis of hepatocellular carcinoma in cirrhotic patients with indeterminate liver nodules.
Mokrane FZ; Lu L; Vavasseur A; Otal P; Peron JM; Luk L; Yang H; Ammari S; Saenger Y; Rousseau H; Zhao B; Schwartz LH; Dercle L
Eur Radiol; 2020 Jan; 30(1):558-570. PubMed ID: 31444598
[TBL] [Abstract][Full Text] [Related]
17. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma.
Capurro M; Wanless IR; Sherman M; Deboer G; Shi W; Miyoshi E; Filmus J
Gastroenterology; 2003 Jul; 125(1):89-97. PubMed ID: 12851874
[TBL] [Abstract][Full Text] [Related]
18. Identification of a Glypican-3-Binding Peptide for In Vivo Non-Invasive Human Hepatocellular Carcinoma Detection.
Qin Z; Wang J; Wang Y; Wang G; Wang X; Zhou Z; Liu G; Gao S; Zhu L
Macromol Biosci; 2017 Apr; 17(4):. PubMed ID: 27862961
[TBL] [Abstract][Full Text] [Related]
19. Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma.
Tremosini S; Forner A; Boix L; Vilana R; Bianchi L; Reig M; Rimola J; Rodríguez-Lope C; Ayuso C; Solé M; Bruix J
Gut; 2012 Oct; 61(10):1481-7. PubMed ID: 22287594
[TBL] [Abstract][Full Text] [Related]
20. Analysis of Lipiodol uptake in angiography and computed tomography for the diagnosis of malignant versus benign hepatocellular nodules in cirrhotic liver.
Langenbach MC; Vogl TJ; von den Driesch I; Kaltenbach B; Scholtz JE; Hammerstingl RM; Gruber-Rouh T
Eur Radiol; 2019 Dec; 29(12):6539-6549. PubMed ID: 31236701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
